Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trialRoser Pinyol, Josep M. Llovet, Han Chu Lee et al.|Gut|2018Cited by 338
Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinomaDaniela Sia, Josep M. Llovet, Bojan Losic et al.|Nature Communications|2015Cited by 302
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinomaRobert Montal, Josep M. Llovet, Daniela Sia et al.|Journal of Hepatology|2020Cited by 301
Abstract 4618: Integrative molecular classification of extrahepatic cholangiocarcinomaRobert Montal, Josep M. Llovet, Wei Qiang Leow et al.|Cancer Research|2018Cited by 0